SAN DIEGO, Aug. 31 /PRNewswire/ -- Sangart, Inc., today announced positive results from its Phase IIa proof-of-concept study of MP4OX (oxygenated pegylated hemoglobin) in severely injured trauma patients with hemorrhagic shock causing lactic acidosis. The study demonstrated that MP4OX, when given in addition to standard of care, was effective at decreasing lactate levels in treated patients. During hemorrhagic shock, inadequate perfusion of critical organs can lead to insufficient oxygenation of tissues, which can be detected by an increase in lactate levels. MP4OX is a novel oxygen therapeutic agent that is designed to provide rapid oxygen delivery to ischemic tissues.
Study data show a statistically significant greater immediate and sustained decrease of lactic acid in patients treated with MP4OX compared to patients in the control group. The study also found that a greater proportion of patients treated with MP4OX were able to attain normal lactate levels as early as four hours post-treatment. Furthermore, data demonstrated a strong trend toward outcomes benefits through multiple measures, including reducing the average total number of days patients spent in hospital. In patients treated with MP4OX, the median hospital stay was half that of the control group. Serious adverse events were of equal rates and similar in nature between the MP4OX-treated and control groups.
"Trauma patients suffer organ dysfunction from shock and lack of oxygen supply to vital tissues. Prolonged lactic acidosis, a marker of shock, correlates with a worse outcome and higher mortality rate. This study suggests that MP4OX has the ability to improve oxygen delivery to the body and subsequently reduce organ failure and other complications," said Karim Brohi, Professor of Trauma Sciences at Barts and the London School of Medicine & Dentistry and lead study investigator. "We are excited by the results from this study as they suggest that MP4OX has the potential to
|SOURCE Sangart, Inc.|
Copyright©2010 PR Newswire.
All rights reserved